biotest ag annual shareholders' meeting...

Prof. Dr. Gregor SchulzBiotest AG - Annual Shareholders' Meeting 2013 0

Prof. Dr. Gregor SchulzChairman of the Board of Management

Biotest AG Annual Shareholders'

Meeting 2013

Prof. Dr. Gregor Schulz 1

Investments. Expansion. Future

Biotest Strategyfor 2020

Biotest AG - Annual Shareholders' Meeting 2013

Cornerstones of the Biotest Strategy

2

InternationalisationMarketing authorisation in further markets

Research and Development Additional indications, new developments

Focus Haematology, clinical immunology, intensive care medicine

Prof. Dr. Gregor SchulzBiotest AG - Annual Shareholders' Meeting 2013

0

100

200

300

400

500

1 2 3 4 5 6 7 8 9

Continue and accelerate growth

3

Biotest Group: Sales 2004-2012 (€ million)*

2004 2005 2006 2007 2008 2009 2010 2011 2012

141.9

339.4

440.0

Sales targetfor 2020:

~ € 1 billion

* On a comparable basis, only pharmaceutical activities



Figures for FY 2012 and Q1 2013


Meeting 2013


Sales grow in line with expectations

5

0

100

200

300

400

500

2011 2012

440.0422.0+4.3%

* Continuing Operations

Sales by region* (€ million)

Germany

Rest of Europe

North/South America

Asia

Other

Prof. Dr. Gregor Schulz

161.5

96.9

121.8

58.5

160.5

89.4

77.6

11.1

74.9

9.8


Significant earnings increase

0

10

20

30

40

2011 2012

Earnings before taxes* (€ million)

+27.6%

28.6

36.5

6

0

10

20

30

40

50

2011 2012

EBIT* (€ million)

+7.5%41.6

44.7

* Continuing Operations


Financial position: stronger equity base

0

100

200

300

400

500

600

700

Current assetsNon-current assetsCurrent liabilitiesNon-current liabilitiesEquity

7

Financial Position of the Biotest Group (€ million)

682.8 682.3

2011

Assets Equity and Liabilities

2012 2011 2012

Equity ratio at end of 2012:

54.1%

682.8 682.3


369.4

147.8

188.3

346.7314.9

367.4370.0

312.8

148.0

164.9


Good start to financial year 2013

0

20

40

60

80

100

120

Q1 2012 Q1 2013


0

2

4

6

8

10

12

Q1 2012 Q1 2013

EBIT (€ million)Sales (€ million)

11.8118.7

10.4107.7+10.2% +13.5%


Biotest stock: attractive investment

9

Closing price on 10th of May 2012 = 100

SDax Biotest ordinary share

Biotest preference share

Biotest AG share price performance vs. SDAX

• Dividends for 2012*:− € 0.50 per ordinary share− € 0.56 per preference

share

• 5th consecutive dividend increase

• Shareholder return**:29% (ordinary shares)33% (preference shares)

* Proposal of the Board of Management and Supervisory Board to the ASM

** Performance May 2012/2013 plus dividend for 2012 (as of 06.05.2013)


May 2012 May 2013


80

90

100

110

120

130

140


Corporate Development and Strategy


Meeting 2013


Milestones in 2012

11

• US authorisation for BivigamTM

• Existing products further developed (including Intratect® 10%)

• International position improved

• Progress made in research and development



BivigamTM strengthens position in the US

• Polyspecific intravenous immunoglobulin, comparable to Intratect®

• FDA authorisation in December 2012

• Excellent efficacy and safety profile

• Successful launch in February 2013, sales volume in line with expectations

• Medium-term market potential: USD 100 million per year


Targeted development of Intratect®

13

• Intratect® 10%

• Immunoglobulin with higher doses

• Geared to outpatient therapy

• Allows faster administration

• 5% solution remains first choice for inpatient treatment


Business further internationalised

14

Biotest: Sales by region 2012


Germany:20.3%

Rest of Europe:36.5%Americas:

13.3%

Asia:27.7%

Other:2.2%


China: moving into a growth market

15

• China is world's third-largest pharmaceutical market

• Double-digit growth rates

• Market entry through reactivation of albumin authorisation

• Distribution partnership with leading Chinese pharmaceutical company


http://www.flaggenbilder.de/china_volksrepublik/china_volksrepublik-fahne-011-wehend-weiss-150x180_flaggenbilder.de.gif.html

Immunoglobulin sales boosted

16

Central/South America• Focus on hepatitis B immunoglobulins:

− Hepatect®

− Zutectra®

• Focus markets: Brazil, Mexico, Colombia, Argentina

Russia• Distribution partnership with Merz Pharma for

immunoglobulins• Utilize established distribution channels for

Haemoctin® (tender contract business)


Greece: meeting our responsibility

17

• Supply to Greek hospitals resumed in early 2013

• Distribution agreement with Vianex

• Strict protections for receivables:− advance payment or German bank

guarantee

• Sales from January to April 2013: € 2.2 million


Development projects are making progress

18

HaematologyClinical Immunology

Intensive Care

Medicine

• BT-062 • IgM concentrate

• Fibrinogen

• Civacir®

• Cytotect ® 70 (BT-094)

• Tregalizumab ®

(BT-061)

• BT-063


Civacir® – immunoglobulin with high potential

19

• Hepatitis C immunoglobulin for reinfection prophylaxis after liver transplantation

• "Orphan drug designation" in Europe and US: 10- and 7-year exclusivity after authorisation (respectively)

• Very high demand:− Currently no reliable prophylaxis for the

critical period immediately after transplantation

− In the EU and US alone, more than 5,000 liver transplants due to hepatitis C each year


Tregalizumab – taking the next step

20

• Lead indications of rheumatoid arthritis (RA) and psoriasis

• Partnership with AbbVie (formerly Abbott)

• Start of phase IIb study with up to 350 patients in the US, Canada and Europe in Q2 2013

• Largest clinical trial in Biotest history


Partnership with ADMA: agreement brings additional potential for Biotest

21

• BPC supplies plasma with very high titres of RSV antibodies and produces this immunoglobulin for ADMA

• Biotest acquires license to market and sell the product in Europe and selected countries in North Africa and the Middle East

• ADMA is in preparation for a phase III trial in the US

US biotech company

Focus on special therapeutic immunoglobulins for treatment of rare diseases


IgM concentrate: development on target

22

• IgM concentrate for effective treatment of sepsis (severe bacterial infection)

• Unique mechanism of action

• Interim analysis of ongoing phase II trial: continuation of development clearly recommended


Fibrinogen – start of clinical development

23

• Fibrinogen deficiency causes severe bleeding

• Fibrinogen from Biotest infusion-ready very quickly

• Phase I/II study began in Q1 2013

• Sales potential: about € 100 million/year

• Better use of raw material blood plasma



Investments. Expansion. FutureBiotest 2020 strategy


Meeting 2013


Demand for immunoglobulins continues to grow

46 49 51 54 56

26 27 28 29 30

35 3944

4955

0

30

60

90

120

150

2011 2012e 2013e 2014e 2015e

USA EU Other

Expected long-term annual growth*

EU: 4.5%

USA: 4.5%

Other: 12%

World: 7%

* Estimates excluding possible potential in Alzheimer's

Mar

ket v

olum

e in

tonn

es

Source of all data: MRB (2012)

107115

123132

141

Prof. Dr. Gregor Schulz 25Biotest AG - Annual Shareholders' Meeting 2013

Investments in further growth

26

• Capacity expansion programme in Dreieich

• Construction of new production plants at HQ

• Duration: 2013 to 2018

• Investment: > € 200 million

• More than 300 additional jobs

Plasma fractionation:

3.1 million litres/year currently: 1.5 m litres/year

Immunoglobulins:

13 t/yearcurrently: 5.5 t/year

Albumin:

72 t/yearcurrently: 21 t/year

Expansion of global capacity to:

* excluding already initiated projects (e.g. filling expansion)


Film


Capital increase as an important financing element

27

• Increase share capital by € 3.7 million or 12.5%

• Issue up to 1.46 million new preference shares from authorised capital

• Subscription right for all shareholders (ordinary shares + preference shares)

• Planned for summer 2013


Vision – our road to 2020

28

• Consistent focus on biological drugs for the therapeutic areas of haematology, immunology and intensive care medicine

• Continuous investment in the development of new therapeutic options

• Worldwide operations with a strong base in Europe and the US

• Awareness of responsibilities

• Focused on growth




Meeting 2013


biotest ag annual shareholders' meeting...

Documents